Navigation Links
Cynvenio Announces New LiquidBiopsy® Test for PD-L2 Expression
Date:9/6/2017

Cynvenio Biosystems, Inc., a leader in liquid biopsy testing technology for personalized medicine, today announced the launch of its PD-L2 expression test. The first of its kind, the new blood test enables highly sensitive and specific profiling and monitoring of PD-L2 expression in cancer cells recovered from a simple blood draw.

Cynvenio’s PD-L2 test is the first commercial RUO test that measures PD-L2 expression in circulating tumor cells (CTCs). Recent study data have shown that PD-L2 expression provides valuable information beyond PD-L1 positivity in predicting clinical response to pembrolizumab (Keytruda®) in head and neck squamous cell carcinoma (HNSCC)?.

“The PD-1 pathway is an important therapeutic target in various cancer types,” commented Paul Dempsey, Ph.D., Chief Scientific Officer at Cynvenio Biosystems. “Our new PD-L2 assay enables researchers to more fully understand another target and another regulator of immune evasion. This may contribute to determining which patients may better respond to checkpoint inhibition.”

For additional information or to order the test, please contact Cynvenio at 888-885-1172.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com, and http://www.liquidbiopsy.com.

?Yearley et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017 Jun 15;23(12):3158-3167.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14665268.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test
2. Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy
3. Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression in Lung Cancer
4. Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea
5. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
6. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
7. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
8. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
9. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
10. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
11. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the ... ffERG/Photopic Negative Response vision test, a new full field electroretinography (ffERG) protocol ... that 6.3 million Americans will have glaucoma, with black Americans having the highest ...
(Date:5/2/2019)... ... May 02, 2019 , ... Researchers from Ambry ... discrepancies between U.S. insurer policies for genetic testing and the 2019 National Comprehensive ... and ovarian cancer (HBOC). , Jill S. Dolinsky, director of clinical ...
(Date:4/18/2019)... ... 18, 2019 , ... Taking a step closer to a ... at Worcester Polytechnic Institute (WPI) has developed a novel process using an unusual ... and other biofuels more economically. , Isobutanol, like ethanol, is an alcohol, but ...
(Date:4/12/2019)... ... April 12, 2019 , ... An ... and will educate about innovative tools and devices being used to enhance cognitive ... more information. , This segment of Advancements will focus on Sound for Life, ...
Breaking Biology Technology:
(Date:6/4/2019)... ... June 04, 2019 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... revenues of $31M, up 12% from Q1-18. The growth is associated with uptick ... operational excellence initiatives worldwide. , Laurent Pruvost , President & CEO of ...
(Date:6/3/2019)... ... June 03, 2019 , ... Stay on top of current hot topics ... industries. Access to all webinars is free, so be sure to register today to ... Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL TRIALS , June ...
(Date:5/31/2019)... (PRWEB) , ... May 30, 2019 , ... Enso Discoveries ... and especially during Military Appreciation Month, as a way to express his gratitude and ... and the company he founded — Enso Discoveries — presented a check ...
Breaking Biology News(10 mins):